Ocugen's gene therapy trial results could redefine geographic atrophy treatment

Ocugen is set to reveal the full results of its Phase 2 ArMaDa trial for OCU410, a gene therapy targeting geographic atrophy, on March 24, 2026, at 2:00 PM CET. The findings will shape the company's regulatory plans for a condition affecting millions in the U.S. and Europe.

Investors have already shown confidence, with Oppenheimer assigning an 'Outperform' rating and a $10 price target, while Chardan Capital maintained a 'Buy' recommendation at $7.

The Phase 2 ArMaDa trial involved 51 patients and tested OCU410's ability to slow lesion growth in geographic atrophy. Interim data released earlier showed a 46% reduction in lesion progression after twelve months among 23 participants, with statistical significance (p=0.015). Independent clinicians, including Lejla Vajzovic, Jay Chhablani, and Victor H. Gonzalez, were brought in to review the trial's findings.

Geographic atrophy currently lacks approved treatments in Europe, while U.S. options provide minimal functional improvement despite generating over a billion dollars annually. Ocugen sees a major opportunity, as the disease affects an estimated two to three million people across both regions.

Financially, Ocugen raised $22.5 million in January, securing funds through to the fourth quarter of 2026. If all outstanding warrants are exercised, the company's cash reserves could extend into early 2027. Despite reporting a $67.8 million net loss in 2025 on $4.4 million in revenue, the firm is pushing ahead with plans to launch a Phase 3 trial for OCU410 in mid-2026.

The company also aims to submit three Biologics License Applications (BLAs) within the next two years. Success in the upcoming trial could help Ocugen meet its ambitious regulatory timeline.

The March 24 results will determine whether OCU410 can advance as a viable treatment for geographic atrophy. If approved, it would enter a market with no effective European options and limited U.S. alternatives.

Ocugen's next steps depend on the data, with a Phase 3 trial and multiple BLA filings planned in the near future.